Q-omics provides the consensus-scored CALCOCO1 profile across patient tissues and cancer cell-line models. CALCOCO1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CALCOCO1 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, CALCOCO1 RNA expression shows 20,501 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, LUAD, and THYM as cancer lineages where CALCOCO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CALCOCO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CALCOCO1 survival associations across molecular data types. CALCOCO1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CALCOCO1 RNA expression–survival associations across cancer types. High CALCOCO1 expression shows unfavorable associations in LUSC and COAD, but favorable associations in UVM, MESO, UCS and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CALCOCO1 RNA expression.
This table summarizes CALCOCO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CALCOCO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CALCOCO1 shows lower tumor expression in LUAD, KICH, BLCA, LUSC, HNSC and UCEC. The LUAD box plot shows higher CALCOCO1 RNA expression in normal versus tumor tissue (log2 FC = −1.625, t-test p < 0.001).
This table shows molecular features associated with CALCOCO1 in patient tissues and cancer cell lines. In patient samples, CALCOCO1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CALCOCO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
